Yamato: Kamwo Meridian (00013.HK) target price raised to 30 Hong Kong dollars, maintained "buy" rating.

According to the Wisdom Financial APP, Daiwa has released a research report stating that based on the downward adjustment of domestic drug sales expectations, the revenue forecast for Hutchison China MediTech (00013.HK) for 2025 to 2027 has been reduced by 16% to 29%. It is now expected that the total drug sales for 2025, 2026, and 2027 will increase by 6%, 21%, and 28% respectively, compared to the previous estimates of 34%, 36%, and 33%; the latest net profit is expected to be $433 million, $30 million, and $40 million, respectively; maintaining a "buy" rating, with the target price lowered from HK$33 to HK$30.